TY - JOUR T1 - Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission identifies community social distancing as the dominant intervention reducing outbreaks JF - medRxiv DO - 10.1101/2020.11.17.20232827 SP - 2020.11.17.20232827 AU - Luke B Snell AU - Chloe L Fisher AU - Usman Taj AU - Blair Merrick AU - Adela Alcolea-Medina AU - Themoula Charalampous AU - Adrian W Signell AU - Harry D Wilson AU - Gilberto Betancor AU - Mark Tan Kia Ik AU - Emma Cunningham AU - Penelope R Cliff AU - Suzanne Pickering AU - Rui Pedro Galao AU - Rahul Batra AU - Stuart J D Neil AU - Michael H Malim AU - Katie J Doores AU - Sam T Douthwaite AU - Gaia Nebbia AU - Jonathan D Edgeworth AU - Ali R Awan AU - The COVID-19 Genomics UK (COG-UK) consortium Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/18/2020.11.17.20232827.abstract N2 - Many healthcare facilities report SARS-CoV-2 outbreaks but transmission analysis is complicated by the high prevalence of infection and limited viral genetic diversity. The contribution of different vectors to nosocomial infection or the effectiveness of interventions is therefore currently unclear. Detailed epidemiological and viral nanopore sequence data were analysed from 574 consecutive patients with a PCR positive SARS-CoV-2 test between March 13th and March 31st, when the pandemic first impacted on a large, multisite healthcare institution in London. During this time the first major preventative interventions were introduced, including progressive community social distancing (CSD) policies leading to mandatory national lockdown, exclusion of hospital visitors, and introduction of universal surgical facemask-use by healthcare-workers (HCW). Incidence of nosocomial cases, community SARS-CoV-2 cases and infection in a cohort of 228 HCWs followed the same dynamic course, decreasing shortly after introduction of CSD measures and prior to the main hospital-based interventions. We investigated clusters involving nosocomial cases based on overlapping ward-stays during the 14-day incubation period and SARS-CoV-2 genome sequence similarity. Our method placed 63 (79%) of 80 sequenced probable and definite nosocomial cases into 14 clusters containing a median of 4 patients (min 2, max 19) No genetic support was found for the majority of epidemiological clusters (31/44, 70%) and genomics revealed multiple contemporaneous outbreaks within single epidemiological clusters. We included a measure of hospital enrichment compared to community cases to increase confidence in our clusters, which were 1-14 fold enriched. Applying genomics, we could provide a robust estimate of the incubation period for nosocomial transmission, with a median lower bound and upper bound of 6 and 9 days respectively. Six (43%) clusters spanned multiple wards, with evidence of cryptic transmission, and community-onset cases could not be identified in more than half the clusters, particularly on the elective hospital site, implicating HCW as vectors of transmission. Taken together these findings suggest that CSD had the dominant impact on reducing nosocomial transmission by reducing HCW infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the King's Together Multi and Interdisciplinary Research Scheme (Wellcome Trust Revenue Retention Award, and the National Institute for Health Research (NIHR) Biomedical Research Centre programme of Infection and Immunity (RJ112/N027) based at Guy's and St Thomas' National Health Service (NHS) Foundation Trust and King's College London. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Favourable opinion to conduct this work was granted by the North West Preston Research Ethics Committee (Reference 18/NW/0584) The COVID-19 Genomics UK (COG-UK) consortium study protocol was approved by the Public Health England Research Ethics and Governance Group (reference: R&D NR0195). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data will be available at ENA Study accession number is: PRJEB41373 Study name is: ena-STUDY-KING'S COLLEGE LONDON-17-11-2020-01:31:23:025-468 ER -